Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow-up

Translated title of the contribution: Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine. 4 Year follow-up results

E. Trespi, C. Colla, P. Panizza, M. G. Polino, A. Venturini, G. Bottani, P. De Vecchi, C. Matti

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

In order to evaluate the efficacy and tolerability of mesalazine (5-ASA) in the prophylaxis of simptomatic relapses, of major complications and of microhemmorrhagic phenomena in diverticular disease of the large intestine (MDC), prospective clinical study was conducted on patients with light- moderate symptomatic MDC under treatment with sulbactam-ampicillin 1.5 g/12 h.i.m. and rifaximine 400 mg/12 h per os for 7 days. Follow-up period of 5 years with seriated checkups and laboratory and instrumentation controls. End points are represented by the relapse on inflammation and/or by the occurrence of major complications. On enrolment, 166 patients were randomized to receive mesalazine (Pentacol® tablets - SOFAR S.p.A.) 400 mg b.i.d. per os for 8 weeks (81 patients; group M) or no supplementary treatment (85 patients; group C). After 4 years of follow-up, 44 patients dropped out of the study (9 because of major complications, 3 for massive hemorrhage, and 32 drop outs). Symptomatic relapses occurred in 51 patients (12 M; 39 C), while minor diverticular hemorrhages occurred in 43 patients (12 M; 31 C), with an estimated probability of remaining free respectively from symptomatic relapse (p=0.00005) and from microhemorrhagic phenomena (p=0.001) decisively in favor of the group treated with mesalazine. The duration of abdominal pain due to diverticolitis was also shorter in patients of group M (p=0.0002), while the incidence of major complications and side effects was comparable in the two groups. In conclusion, supplementary treatment with mesalazine in patients affected with MDC - at a follow-up limited to 48 months - proved to be well tolerated and effective in reducing the frequency of symptomatic relapses and microhemorrhagic phenomena and in reducing the duration of abdominal pain.

Original languageItalian
Pages (from-to)245-252
Number of pages8
JournalMinerva Gastroenterologica e Dietologica
Volume45
Issue number4
Publication statusPublished - 1999

Fingerprint

Mesalamine
Large Intestine
Recurrence
Therapeutics
Abdominal Pain
Hemorrhage
Tablets
Prospective Studies
Inflammation
Light

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow-up. / Trespi, E.; Colla, C.; Panizza, P.; Polino, M. G.; Venturini, A.; Bottani, G.; De Vecchi, P.; Matti, C.

In: Minerva Gastroenterologica e Dietologica, Vol. 45, No. 4, 1999, p. 245-252.

Research output: Contribution to journalArticle

@article{96a0a33c41e44a4da7822741ff592026,
title = "Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow-up",
abstract = "In order to evaluate the efficacy and tolerability of mesalazine (5-ASA) in the prophylaxis of simptomatic relapses, of major complications and of microhemmorrhagic phenomena in diverticular disease of the large intestine (MDC), prospective clinical study was conducted on patients with light- moderate symptomatic MDC under treatment with sulbactam-ampicillin 1.5 g/12 h.i.m. and rifaximine 400 mg/12 h per os for 7 days. Follow-up period of 5 years with seriated checkups and laboratory and instrumentation controls. End points are represented by the relapse on inflammation and/or by the occurrence of major complications. On enrolment, 166 patients were randomized to receive mesalazine (Pentacol{\circledR} tablets - SOFAR S.p.A.) 400 mg b.i.d. per os for 8 weeks (81 patients; group M) or no supplementary treatment (85 patients; group C). After 4 years of follow-up, 44 patients dropped out of the study (9 because of major complications, 3 for massive hemorrhage, and 32 drop outs). Symptomatic relapses occurred in 51 patients (12 M; 39 C), while minor diverticular hemorrhages occurred in 43 patients (12 M; 31 C), with an estimated probability of remaining free respectively from symptomatic relapse (p=0.00005) and from microhemorrhagic phenomena (p=0.001) decisively in favor of the group treated with mesalazine. The duration of abdominal pain due to diverticolitis was also shorter in patients of group M (p=0.0002), while the incidence of major complications and side effects was comparable in the two groups. In conclusion, supplementary treatment with mesalazine in patients affected with MDC - at a follow-up limited to 48 months - proved to be well tolerated and effective in reducing the frequency of symptomatic relapses and microhemorrhagic phenomena and in reducing the duration of abdominal pain.",
keywords = "Diverticulitis, colonic drug therapy, Diverticulitis, colonic prevention and control, Mesalamine",
author = "E. Trespi and C. Colla and P. Panizza and Polino, {M. G.} and A. Venturini and G. Bottani and {De Vecchi}, P. and C. Matti",
year = "1999",
language = "Italian",
volume = "45",
pages = "245--252",
journal = "Minerva Gastroenterologica",
issn = "0026-4776",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Risultati a 4 anni di follow-up

AU - Trespi, E.

AU - Colla, C.

AU - Panizza, P.

AU - Polino, M. G.

AU - Venturini, A.

AU - Bottani, G.

AU - De Vecchi, P.

AU - Matti, C.

PY - 1999

Y1 - 1999

N2 - In order to evaluate the efficacy and tolerability of mesalazine (5-ASA) in the prophylaxis of simptomatic relapses, of major complications and of microhemmorrhagic phenomena in diverticular disease of the large intestine (MDC), prospective clinical study was conducted on patients with light- moderate symptomatic MDC under treatment with sulbactam-ampicillin 1.5 g/12 h.i.m. and rifaximine 400 mg/12 h per os for 7 days. Follow-up period of 5 years with seriated checkups and laboratory and instrumentation controls. End points are represented by the relapse on inflammation and/or by the occurrence of major complications. On enrolment, 166 patients were randomized to receive mesalazine (Pentacol® tablets - SOFAR S.p.A.) 400 mg b.i.d. per os for 8 weeks (81 patients; group M) or no supplementary treatment (85 patients; group C). After 4 years of follow-up, 44 patients dropped out of the study (9 because of major complications, 3 for massive hemorrhage, and 32 drop outs). Symptomatic relapses occurred in 51 patients (12 M; 39 C), while minor diverticular hemorrhages occurred in 43 patients (12 M; 31 C), with an estimated probability of remaining free respectively from symptomatic relapse (p=0.00005) and from microhemorrhagic phenomena (p=0.001) decisively in favor of the group treated with mesalazine. The duration of abdominal pain due to diverticolitis was also shorter in patients of group M (p=0.0002), while the incidence of major complications and side effects was comparable in the two groups. In conclusion, supplementary treatment with mesalazine in patients affected with MDC - at a follow-up limited to 48 months - proved to be well tolerated and effective in reducing the frequency of symptomatic relapses and microhemorrhagic phenomena and in reducing the duration of abdominal pain.

AB - In order to evaluate the efficacy and tolerability of mesalazine (5-ASA) in the prophylaxis of simptomatic relapses, of major complications and of microhemmorrhagic phenomena in diverticular disease of the large intestine (MDC), prospective clinical study was conducted on patients with light- moderate symptomatic MDC under treatment with sulbactam-ampicillin 1.5 g/12 h.i.m. and rifaximine 400 mg/12 h per os for 7 days. Follow-up period of 5 years with seriated checkups and laboratory and instrumentation controls. End points are represented by the relapse on inflammation and/or by the occurrence of major complications. On enrolment, 166 patients were randomized to receive mesalazine (Pentacol® tablets - SOFAR S.p.A.) 400 mg b.i.d. per os for 8 weeks (81 patients; group M) or no supplementary treatment (85 patients; group C). After 4 years of follow-up, 44 patients dropped out of the study (9 because of major complications, 3 for massive hemorrhage, and 32 drop outs). Symptomatic relapses occurred in 51 patients (12 M; 39 C), while minor diverticular hemorrhages occurred in 43 patients (12 M; 31 C), with an estimated probability of remaining free respectively from symptomatic relapse (p=0.00005) and from microhemorrhagic phenomena (p=0.001) decisively in favor of the group treated with mesalazine. The duration of abdominal pain due to diverticolitis was also shorter in patients of group M (p=0.0002), while the incidence of major complications and side effects was comparable in the two groups. In conclusion, supplementary treatment with mesalazine in patients affected with MDC - at a follow-up limited to 48 months - proved to be well tolerated and effective in reducing the frequency of symptomatic relapses and microhemorrhagic phenomena and in reducing the duration of abdominal pain.

KW - Diverticulitis, colonic drug therapy

KW - Diverticulitis, colonic prevention and control

KW - Mesalamine

UR - http://www.scopus.com/inward/record.url?scp=0033375975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033375975&partnerID=8YFLogxK

M3 - Articolo

C2 - 16498335

AN - SCOPUS:0033375975

VL - 45

SP - 245

EP - 252

JO - Minerva Gastroenterologica

JF - Minerva Gastroenterologica

SN - 0026-4776

IS - 4

ER -